Shares of Baxter International Inc (NYSE:BAX) have been given an average recommendation of “Buy” by the seventeen ratings firms that are covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $70.23.
BAX has been the topic of several recent research reports. Zacks Investment Research upgraded Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price objective on the stock in a research report on Tuesday, October 24th. Morgan Stanley increased their target price on Baxter International from $59.00 to $62.00 and gave the company an “equal weight” rating in a research report on Thursday, October 26th. Barclays increased their target price on Baxter International from $70.00 to $73.00 and gave the company an “overweight” rating in a research report on Thursday, October 26th. Stifel Nicolaus reiterated a “hold” rating and set a $65.00 target price on shares of Baxter International in a research report on Thursday, October 26th. Finally, Royal Bank of Canada reiterated a “hold” rating and set a $66.00 target price on shares of Baxter International in a research report on Wednesday, November 22nd.
Baxter International (NYSE:BAX) traded down $0.11 during trading on Tuesday, reaching $66.33. The company’s stock had a trading volume of 3,709,756 shares, compared to its average volume of 3,460,000. The company has a current ratio of 2.80, a quick ratio of 2.22 and a debt-to-equity ratio of 0.37. Baxter International has a 1-year low of $49.30 and a 1-year high of $72.58. The stock has a market cap of $36,140.00, a price-to-earnings ratio of 51.02, a PEG ratio of 1.91 and a beta of 0.78.
In other Baxter International news, SVP Giuseppe Accogli sold 28,641 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total value of $1,918,947.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jeanne K. Mason sold 33,350 shares of the firm’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $65.25, for a total value of $2,176,087.50. Following the completion of the transaction, the senior vice president now owns 124,609 shares in the company, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Sawtooth Solutions LLC purchased a new stake in Baxter International during the fourth quarter worth $239,000. HM Payson & Co. boosted its position in Baxter International by 4.7% during the fourth quarter. HM Payson & Co. now owns 54,490 shares of the medical instruments supplier’s stock worth $3,522,000 after purchasing an additional 2,432 shares in the last quarter. Banco de Sabadell S.A purchased a new stake in Baxter International during the fourth quarter worth $4,697,000. Meitav Dash Investments Ltd. purchased a new stake in Baxter International during the fourth quarter worth $1,243,000. Finally, Segall Bryant & Hamill LLC boosted its position in Baxter International by 2.3% during the fourth quarter. Segall Bryant & Hamill LLC now owns 421,520 shares of the medical instruments supplier’s stock worth $27,247,000 after purchasing an additional 9,466 shares in the last quarter. Institutional investors own 83.12% of the company’s stock.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.